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Abstract 
The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 
years. Most patients with chronic phase (CP) now have a normal life expectancy. Another goal is achieving 
a stable deep molecular response (DMR) and discontinuing medication for treatment-free remission 
(TFR). The European LeukemiaNet convened an expert panel to critically evaluate and update the evi-
dence to achieve these goals since its previous recommendations. First-line treatment is a tyrosine kinase 
inhibitor (TKI; imatinib brand or generic, dasatinib, nilotinib, and bosutinib are available first-line). Generic 
imatinib is the cost-effective initial treatment in CP. Various contraindications and side-effects of all TKIs 
should be considered. Patient risk status at diagnosis should be assessed with the new EUTOS long-term 
survival (ELTS)-score. Monitoring of response should be done by quantitative polymerase chain reaction 
whenever possible. A change of treatment is recommended when intolerance cannot be ameliorated or 
when molecular milestones are not reached.  Greater than 10% BCR-ABL1 at 3 months indicates treatment 
failure when confirmed. Allogeneic transplantation continues to be a therapeutic option particularly for 
advanced phase CML. Preferably, TKI treatment should be withheld during pregnancy. Treatment discon-
tinuation may be considered in patients with durable DMR with the goal of achieving TFR. 
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Introduction 
The life expectancy of a newly diagnosed patient with Philadelphia chromosome-positive (Ph+), BCR-
ABL1+ chronic myeloid leukemia (CML) in chronic phase (CP) is now very close to that of age matched 
individuals in the general population, at least in Western countries.1-5 This remarkable achievement re-
flects the success of a large number of prospective clinical trials, summarized in management recommen-
dations previously published by the European LeukemiaNet (ELN).6-8 Several tyrosine kinase inhibitors 
(TKIs) are approved for the treatment of CML and the choice of therapies for individual patients is deter-
mined by considerations of efficacy, tolerability, early and late toxicity and drug costs. More recently, 
there has been increasing focus on quality of life and avoiding long-term organ toxicities and, in particular, 
the identification of strategies to maximize the possibility of stopping TKI therapy resulting in so-called 
“treatment free remission” (TFR). However, in resource-poor countries, the availability of effective drugs 
and essential monitoring may be limited, and the goal of treatment remains survival.9 
Since management goals and therapeutic scenarios continue to evolve, the ELN again appointed an inter-
national panel of experts to update the previous recommendations8. The current recommendations are 
based insofar as possible on high quality evidence reported in peer-reviewed journals, supplemented by 
the consensus of the panel. The recommendations are geared towards those medical professionals treat-
ing patients with CML and towards concerned patients to provide better understanding of their disease 
and their treatment. 
 
Methods 
The ELN panel for recommendations in CML comprises thirty-four experts from Europe, America, and the 
Asian-Pacific areas. The panel met six times at international meetings of the American Society of Hema-
tology (2015, 2016), the European School of Hematology (2017), the European LeukemiaNet (2019), the 
European Investigators on CML (2019) and the European School of Haematology/International CML Foun-
dation (2019). Five sets of key questions were submitted to panel members to complement the meetings. 
Discordant opinions were harmonized by email discussions, and a consensus of 75%-100% was reached 
in most, but not all instances. Unresolved controversies are described in the discussion section. The costs 
of the meetings and the preparation of the interim and final reports were born entirely by ELN, a research 
network of excellence initiated by the European Union, now funded by donations and projects of ELN 
participants. There was no financial support from industry for any activity. Treatment recommendations 
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are limited to the TKIs that have been approved with at least one indication in CML, either by the US 
Federal Drug Administration (FDA) or/and by the European Medicine Agency (EMA). The drugs are listed 
in the order of FDA approval. The panel acknowledges that not all drugs may be available worldwide and 
that the high price of some makes access to these drugs problematic in some countries.  
Relevant papers published after the third version of the ELN recommendations in 2013 were identified 
through the PubMed database and were critically reviewed. With few exceptions, only papers published 
after 2013 are cited here. The panel also reviewed and utilized as appropriate abstracts presented at the 
recent meetings of the American Society of Clinical Oncology, the European Hematology Association and 
the American Society of Hematology.  
The definitions of hematologic, cytogenetic, and molecular responses were maintained from previous 
versions.6-8 
 
Clinical care 
The goal of CML treatment is normal survival and good quality of life without life-long treatment.2, 4, 10, 11  
Specialty care for complications of chronic TKI therapy is required for optimal management. CML is no 
longer a disease that is fatal in a few years. Rather, it has evolved into a chronic condition with age-related 
comorbidities. Leukemia, therefore, is no longer the primary cause of disability and death. CML, a rare 
disease, requires specific competence to deal with its treatment and its complications12. The therapy is 
expensive and life-saving, but only if planned and supervised by trained clinicians. Treatment should be 
managed in cooperation with a specialized referral centre where there is rapid access to quality-con-
trolled, reliable tests including chromosome banding analysis (CBA), fluorescence in-situ hybridization 
(FISH) for specific cases, and quantitative reverse transcriptase polymerase chain reaction (qPCR) with 
mutation analysis (Sanger or next generation sequencing, NGS).12 
 
Diagnostic work-up 
When CML is diagnosed, a bone marrow aspirate is required for morphology, since the proportion of blast 
cells and of basophils is important to distinguish CP from accelerated phase (AP) and blastic phase (BP), 
and for cytogenetics. A core biopsy may be done to evaluate the degree of fibrosis which has prognostic 
importance and may identify nests of blasts not evident in the aspirate.13-15 Cytogenetics should be 
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performed by CBA of Giemsa-stained metaphases from bone marrow cells. A qualitative reverse tran-
scriptase PCR on peripheral blood cells is mandatory to identify the type of BCR-ABL1 transcripts that can 
be appropriately followed when assessing response to TKI therapy. About 2-4% of patients harbor atypical 
BCR-ABL1 transcripts lacking ABL1 exon2 (e13a3 or e14a3) or resulting from atypical BCR breakpoints 
(e.g., e1a2, e6a2, e8a2, or e19a2) that may yield a false negative PCR using routine primer/probe sets in 
qualitative or quantitative reverse transcriptase PCR protocols. If not tested at diagnosis, a false impres-
sion may be given that a patient is in complete molecular response after TKI treatment. A quantitative 
PCR is not mandatory at diagnosis. If a molecular assay demonstrates BCR-ABL1, but the Ph-chromosome 
cannot be identified by cytogenetics, a FISH test is required. The diagnostic work-up is completed by a 
physical examination with particular reference to spleen and liver size, a standard biochemical profile 
including hepatitis B serology, cholesterol, lipase and hemoglobin A1c values, and an electrocardiogram 
(Table 1). 
 
Table 1 
 
Performing other tests and diagnostic procedures depends on characteristics of the individual patient, 
medical history, and comorbidities. 
The definitions of CP, AP and BP are based on hematologic and clinical parameters and unchanged from 
previous published versions.6-8 However, resistance to two TKIs, detection of a BCR-ABL1 kinase domain 
(KD)-mutation, or emergence of additional chromosome abnormalities in Ph+ cells (ACA) raise concerns 
for progression of disease.16-19  
 
Epidemiology 
In Western countries the median age of CML patients is about 57 years.4, 19, 20 Patients older than 70 years 
make up more than 20% and children and adolescents less than 5%.   
In Asia and in Africa the median age at diagnosis is less than 50 years, reflecting in part the lower median 
age of the population.9 Age is an important variable in the choice of treatment, because overall survival, 
comorbidities, and the development of complications are all age-related. TFR may be the main goal for 
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any patient, irrespective of age, but it is clear that the younger the patient the stronger the case for 
achieving TFR. The recommendations presented here are primarily intended for the use in adult patients, 
as the biology of pediatric patients and their treatment exhibit unique characteristics. 
 
Baseline prognostic factors 
Three prognostic systems, Sokal, Euro, and EUTOS, logarithmically derived, but based on simple clinical 
and hematologic data, have been used to estimate the survival risk at baseline21-23. The Sokal score has 
been particularly popular and was used in most TKI-trials.21 These risk scores were designed to evaluate 
differences in survival21, 22 or response23. Since most patients now die from causes other than leukemia 
while still in remission, a fourth risk score has been developed to predict the probability of dying from 
CML (leukemia-related death, LRD):  the new EUTOS Long Term Survival (ELTS) score.24-26 The ELTS score, 
based on TKI treated patients, uses the same simple hematologic data, spleen size and age as Sokal. The 
main difference is in the negative prognostic value of age, since it has less impact in TKI-treated patients 
(ELTS) than in patients treated with conventional chemotherapy (Sokal). The Sokal score apportions more 
patients to the intermediate- and high-risk groups than ELTS, particularly among older patients (Table 2).  
The panel recommends the use of the new ELTS survival score. Prognostic scores at baseline of CP CML 
and calculation of relative risk as well as a comparison of Sokal and ELTS scores are shown in Table 2.21, 24 
A score calculator is accessible via http://www.leukemia-net.org/content/leukemias/cml/elts_score/in-
dex_eng.html.  
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Table 2 
 
Several additional risk factors have been identified, but so far none has been validated and found useful 
with the exception of fiber content in bone marrow biopsies13-15 and high-risk ACA 16-18. These include +8, 
a second Ph-chromosome (+Ph), i(17q), +19, -7/7q-, 11q23 or 3q26.2 aberrations, and complex aberrant 
karyotypes.  High-risk ACA predict a poorer response to TKIs and a higher risk of progression.16-18 In the 
last version of the recommendations, ACA were mentioned as a “warning”.8 Currently, the panel recom-
mends classifying ACA and treating patients with high-risk ACA as high-risk patients. 
 
Molecular response definitions 
 
Table 3 
 
Molecular response must be assessed according to the International Scale (IS) as the ratio of BCR-ABL1 
transcripts to ABL1 transcripts, or to other internationally accepted control transcripts (e.g. beta glucu-
ronidase, GUSB, for testing high BCR-ABL1 levels at baseline, after relapse, or in advanced disease), and 
must be expressed and reported as BCR-ABL1 % on a log scale, where 1%, 0.1%, 0.01%, 0.0032%, and 
0.0001% correspond to a decrease of 2, 3, 4, 4.5, and 5 logs, respectively, below the standardized baseline 
that was used in the IRIS study.27-29 BCR-ABL1 <1% is equivalent to complete cytogenetic remission, 
CCyR.30 BCR-ABL1 transcript level ≤ 0.1% is defined as major molecular response (MMR) or MR3. A BCR-
ABL1 transcript level ≤ 0.01% or by undetectable disease in cDNA with >10,000 ABL1 transcripts is defined 
as MR4. A BCR-ABL1 transcript level ≤0.0032% or by undetectable disease in cDNA with >32,000 ABL1 
transcripts in the same volume of cDNA used to test for BCR-ABL1 is defined as MR4.5. Assay sensitivity 
should be defined in a standardized manner when BCR-ABL1 mRNA is undetectable. The term "complete 
molecular response" should be avoided and substituted by the term “molecularly undetectable leukemia” 
with specification of the number of the control-gene transcripts. These working definitions depend criti-
cally on the ability of testing laboratories to measure absolute numbers of control gene transcripts in a 
comparable manner (Table 3) and on their ability to achieve the PCR sensitivity required for BCR-ABL1 
detection.31, 32 
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Monitoring, response to treatment, and milestones 
Blood cell counts and differential cell counts are required every two weeks until a complete hematologic 
response is achieved or, more frequently, in the event of hematologic toxicity. QPCR on blood cells, ex-
pressed as BCR-ABL1 % according to the IS, must be performed at least every 3 months even after an 
MMR is achieved and confirmed, because close monitoring of molecular response is required to assess 
eligibility for treatment discontinuation. Cytogenetics, by CBA of marrow cell metaphases, may be useful 
when performed, but alone is not sufficiently sensitive to monitor response. However, cytogenetics 
should be done in patients with atypical translocations, rare or atypical BCR-ABL1 transcripts that cannot 
be measured by qPCR, treatment failure/resistance to exclude ACA, and with progression to AP or BP. 
FISH monitoring may be needed in patients with atypical transcripts.  
The monitoring milestones of BCR-ABL1 transcript levels by the IS at 3, 6, and 12 months (Table 4) deter-
mine whether the current treatment should be continued (optimal response), changed (failure/re-
sistance), or carefully considered for continuation or change, depending on patients´ characteristics, 
comorbidities and tolerance (warning). Additional qPCR testing may be indicated if the kinetics of the 
response are not clear, or if toxicity or intolerance cause dose interruptions or reductions. The same def-
initions are recommended for second-line treatment. Achieving an MMR (BCR-ABL1 ≤ 0.1%) predicts a 
CML-specific survival close to 100% as disease progression is uncommon once this level of cytoreduction 
has been achieved. 
 
Table 4 
 
First-line treatment 
With the exception of cases of CML newly diagnosed during pregnancy, first-line treatment is a TKI. A 
short course of hydroxyurea may be given in symptomatic patients with high white blood cell or platelet 
counts while molecular and cytogenetic confirmation of the CML diagnosis is pending. Currently, four TKIs 
have been approved for first-line treatment by the FDA and EMA: imatinib (Glivec®, Novartis, or generic), 
dasatinib (Sprycel®, Bristol-Myers Squibb), nilotinib (Tasigna®, Novartis), and bosutinib (Bosulif®, Pfizer). 
These are available almost everywhere, though with some differences in indications, dosing, and reim-
bursement. A fifth TKI, radotinib (Supect®, Dae Wong Pharmaceuticals) has been approved in South Korea 
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only. Dasatinib, nilotinib, bosutinib and radotinib have been tested against imatinib in company spon-
sored randomized trials. They have never been tested against each other. The results of these trials have 
provided the basis for approval of these TKIs in the first-line setting. Comparisons among these trials, and 
of these trials with academic studies, are difficult because of differences in protocols and methods of 
evaluation.33 
 
Imatinib 
Imatinib, the first generation TKI was tested in the IRIS study, where it showed higher rates of cytogenetic 
and molecular responses compared to a combination of recombinant interferon alpha (IFNα) and low-
dose cytarabine34 and better progression-free (PFS) and overall survival (OS).35 Imatinib immediately be-
came the first-line choice for the treatment of CML. Three academic trials36-39 rapidly confirmed and ex-
tended IRIS by testing imatinib in combination with IFN or low-dose cytarabine and at higher dosage, 
providing benchmarks for deep molecular responses, and demonstrating normal life expectancy in most 
patients. Additional information on imatinib came from other academic prospective and retrospective 
studies as well as from population-based registries.1, 2 Imatinib served as control arm in six prospective 
pharmaceutical company-sponsored trials testing dasatinib, nilotinib, bosutinib, and radotinib)40-45 and in 
three prospective academic trials testing dasatinib.46-48  
The standard dose of imatinib is 400 mg once daily. In CP a lower dose of 300 mg can be used if 400 mg is 
not tolerated and the response is optimal. A dose of 400 mg twice daily can be used in AP, but in patients 
with progression to more advanced disease a change to 2GTKI is recommended. 
Following imatinib treatment, early molecular response rates at 3 and 6 months (BCR-ABL1 ≤ 10%) range 
between 60% and 80%. At one and 5-years, MMR rates range between 20% - 59% and 60% - 80%, respec-
tively. The 5-year probability of achieving a DMR (MR4 or deeper) ranges between 35% - 68%. Changes of 
imatinib, mostly to another TKI, range from 26.5% within 10 years4 to as high as 37% and 50% within 5 
years40, 41. Five-year PFS and OS range between 80% - 90% and 90% - 95%, respectively. Ten-year OS 
ranges between 82% and 85% with a leukemia-related death rate of about 6%.4, 35 
No absolute contraindications have been reported for the use of imatinib, and no life-threatening com-
plications have surfaced although patients with a low cardiac ejection fraction and a low glomerular fil-
tration rate should be observed carefully for related organ toxicity.4, 35 The most frequent causes of poor 
tolerance have been early fluid retention, gastrointestinal symptoms, muscle cramps, joint pain, skin rash 
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and fatigue.37, 49 Many of these adverse events resolved over time or after a brief drug holiday. A dose 
reduction may be considered in patients who achieved an MMR.50 
 
Dasatinib 
Dasatinib is a second generation TKI (2GTKI), more potent than imatinib and active against several 
imatinib-resistant BCR-ABL1 mutations (Table 5). The DASISION trial40, comparing dasatinib, 100 mg once 
daily, with imatinib, 400 mg once daily, with a minimum follow-up of 5 years, showed that with dasatinib 
the early molecular response rate (84%), the MMR rate by one year (46%), the five-year cumulative prob-
abilities of achieving MMR (76%) and MR4.5 (42%) were significantly higher, but PFS and OS were similar 
(86% vs 85% and 91% vs 95%, respectively). The rate of changing from either primary treatment was sim-
ilar, 39% vs 37%. Three academic studies with 1-5 years follow-up reported similar data.46-48  
The approved CP dose of dasatinib is 100 mg once daily for CP, and 70 mg twice daily for advanced phase 
CML. An increase of the dose is not recommended. Because of fewer side-effects at similar response rates 
in CP, a dose as low as 50 mg is an option.51 
Dasatinib has pleuro-pulmonary toxicity so that respiratory failure and previous or concomitant pleuro-
pulmonary or pericardial diseases are strong contraindications to the use of dasatinib as first-line manag-
ing. Chronic complications include recurrent pleural effusions in as many as 37% of patients; this may 
occur even after years of previously uncomplicated treatment. Rarely pulmonary arterial hypertension is 
observed.40 Aside from these side-effects, tolerability was the same as with imatinib.40  
 
Nilotinib 
Nilotinib, another 2GTKI that is more potent than imatinib, inhibits several imatinib-resistant BCR-ABL1 
mutations (Table 5). The ENESTnd trial41 compared nilotinib, 300 mg twice daily with imatinib, 400 mg 
once daily, now with a minimum follow-up of 10 years.52 Following nilotinib treatment, the 5- and 10-year 
cumulative probabilities for achieving MMR were 77% and 82.6%, MR4 (66% and 73%) and MR4.5 (54% 
and 64%), respectively. Although these results were significantly better than with imatinib, nevertheless 
5- and 10-year OS were similar (94% vs 92% and 87.6% vs 88.3%, respectively). The rates of changing 
primary treatment were 40% for nilotinib and 50% for imatinib. In a phase II study of 73 newly diagnosed 
CP patients, the 10-year intention to treat outcome was 98% MMR, 76% MR4, and 94% OS.53 Another 
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randomized study of nilotinib vs imatinib in first-line, ENESTchina42, revealed similar response data by one 
year; approximately the same results have been reported in other company sponsored (ENEST1st,54) and 
academic studies.3, 55  
The approved dose of nilotinib is 300 mg twice daily in first-line treatment and 400 mg twice daily beyond 
first-line. A dose of more than 300 mg twice daily should be used cautiously owing to a dose-related in-
crease in the risk of cardiovascular side-effects.41, 52, 53, 55  
Cardiovascular events occurred in about 20% of patients over a 10-year period52 compared to 5% with 
imatinib. A history of either coronary heart disease, cerebrovascular accidents, or peripheral arterio-oc-
clusive disease represents a strong contraindication for using nilotinib as first-line therapy. Patients with 
hypertension, hypercholesterolemia, and diabetes mellitus may also be at increased risk and, because 
pancreatitis has been reported in about 5% of treated patients, a history of pancreatitis also represents a 
contraindication to nilotinib use.  
 
Bosutinib 
Bosutinib is the third 2GTKI that is more potent than imatinib. It also inhibits several BCR-ABL1 mutations 
(Table 5). The registration trial BFORE compared bosutinib with imatinib, each at 400 mg once daily.43 
After a median follow-up of less than 2 years, early molecular response rate (75%) and one-year MMR 
rate (47%) with bosutinib were significantly higher than with imatinib.43  
The approved dose is 400 mg once daily in first-line, and 500 mg once daily44 in second-line. An increase 
of these doses is not advised. A lower dose may be considered if 500 or 400 mg are not tolerated and the 
response remains optimal. No relevant comorbidities and no strong contraindications have been identi-
fied. Typically transient diarrhea occurs in as many as 30% of patients which can be an annoying side-
effect. Transient elevations of transaminases may occur, mostly in the first weeks to months of treatment. 
 
Radotinib 
Radotinib is a fourth 2GTKI that has been approved in first-line for South Korea, but this drug has not been 
reviewed by the FDA or the EMA. Radotinib is structurally very similar to nilotinib and exhibits an almost 
identical activity profile against BCR-ABL1 mutations. The registration trial (RERISE)45 and the 4-year 
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update56 indicated that molecular response rates were significantly higher with radotinib at 300 mg twice 
daily than with imatinib. No relevant comorbidities or strong contraindications have been reported, thus 
far. A frequent increase of transaminase levels has been noted. 
 
Interferon α (IFNα) 
In the pre-TKI era, IFNα was the treatment of choice. With the advent of pegylated (PEG) formulations 
that require less frequent administration and have improved efficacy and tolerability, IFNα may re-
emerge as a therapeutic option in CP-CML.57 Combinations of 2GTKIs with PEG-IFNα suggest some bene-
fits compared to historical controls in small single arm studies.58, 59 PEG-IFNα in combination with imatinib 
produced deeper and faster responses in two randomized trials, although no long-term survival benefit 
was demonstrated.38, 60 Randomized investigational trials of PEG-IFNα in combination with nilotinib are 
ongoing. The hope in these studies is that PEG-IFNα may increase the proportion of patients qualifying 
for TFR because of its immunological effect. 
 
Generics 
Generic imatinib61-63 is now available worldwide and generic dasatinib is soon to be released.  Quality 
generics have advantages in that the cost of therapy is often significantly reduced, making the drugs more 
affordable and hence more available to patients with limited resources. This should also help with com-
pliance issues, because patients are delinquent in self-medication when required to pay in part or in full 
for their drugs.64, 65 
As long as a generic drug meets the national standards of the country involved in terms of quality of 
production, bioavailability and efficacy, then it is an acceptable alternative to the brand product. Generic 
and brand product dosing should be the same. Monitoring the response to generics must be the same as 
with branded drugs, but if a patient is changed from a brand to a generic product, then enhanced vigilance 
for the first six months in terms of sustaining response and observing for new adverse events is advisable. 
It is recommended that the patient continues to use the same generic brand if at all possible, in order to 
avoid potential side-effects due to changes in drug structure, bioavailability and excipient.  
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TKI costs and cost-effectiveness 
Since adherence to life-long TKI therapy is critical for most patients with CML64, 65, TKI-costs and cost-
effectiveness have become important issues for patients and society, which is justifiably involved in drug 
costs. Life-long costs are an important variable when deciding on a first-line TKI and changing to alterna-
tive drugs in the course of treatment. The potential for a prolonged TFR and discontinuation of all treat-
ment are also involved in these issues.  Several studies have analyzed cost-effectiveness of frontline treat-
ments in various scenarios including strategies to increase the rate of sustained DMR to potentially in-
crease the rate of TFR.66-69 The conclusion is that generic imatinib is the cost-effective initial treatment 
strategy for CML-CP. Until 2GTKI lose patent protection, cost-effectiveness will continue to be an im-
portant issue in choosing first-line TKI because 80% of patients will never achieve a TFR. 
 
Second-line treatment 
Treatment is often changed from the first-line TKI for several reasons. In cases of failure/resistance, the 
change is mandatory and must be accompanied by investigation of BCR-ABL1 KD-mutations (Table 5).70-
73 In case of intolerance and treatment related complications, the decision to change is in part subjective, 
depending upon the patient, physician, options for supportive care, and also upon the level of response. 
In case of warning, the change is optional, depending on the decision of pursuing a policy of early treat-
ment discontinuation as well as on patient-related factors, such as age, lifestyle, comorbidities, and tol-
erance. In the absence of BCR-ABL1 KD-mutations, there can be no clear recommendation for any partic-
ular 2GTKI: all second-line TKIs are effective, but there are no studies comparing the TKIs with each other. 
The criteria for the choice of the second-line TKI are almost entirely patient-related and depend on age, 
comorbidities, toxicity of first TKI, etc. All patients need to continue daily TKIs in CP and in AP/BP. In the 
absence of alternatives, a TKI should be continued even among CP-patients who do not achieve cytoge-
netic response, because TKI still seem to confer a survival advantage in this situation although there are 
no systematic studies in this scenario or biologic studies to explain this observation. All approved first-line 
TKIs are available for second-line use in the doses reported previously.  
The definition of the response (milestones) to second-line treatment should be the same as to first-line 
treatment (Table 4). 
 
  15 
Treatment beyond second-line 
The definition of an acceptable response to third, fourth, or fifth-line treatment cannot be formalized, but 
a BCR-ABL1 transcript level >1% or a cytogenetic response less than complete (Ph+ >0%) are insufficient 
for optimal survival. There are no comparative studies and the choice of TKI should be guided by the 
sensitivity profile of specific BCR-ABL1 KD-mutations if possible, and, in particular T315I where only 
ponatinib is efficacious (Table 5). Suboptimal response to two or more TKIs should lead to prompt consid-
eration of an allogeneic stem cell transplantation (allo-SCT). 
 
Ponatinib 
Ponatinib (Iclusig®, Takeda/Incyte) is a third generation TKI more potent than all other TKIs.74-77 Ponatinib 
has been approved for patients with the BCR-ABL1 T315I mutation and for patients with CML resistant to 
two or more TKIs.74 In patients with resistance to a 2GTKI without specific mutations ponatinib is preferred 
rather than an alternative 2GTKI unless cardiovascular risk factors preclude its use.75, 77  
The FDA approved dose of ponatinib is 45 mg once daily. Cardiovascular toxicity can occur in about 30% 
of recipients75 and may be dose-related; the panel advises starting at a lower dose (30 mg or 15 mg daily) 
for patients with lesser degrees of resistance or multiple intolerances, especially those with an increased 
cardiovascular risk profile. The dose is increased only if needed. The panel recommends starting with 45 
mg once daily only in patients with T315I, or compound mutations, or progression to an advanced phase. 
Control of hypertension, hyperlipidemia and diabetes and smoking cessation should be emphasized to 
possibly reduce the risk of arterial occlusion events (AOE). The benefit of prophylactic aspirin or anticoag-
ulation is uncertain. Preliminary data suggest that if a CCyR or MMR is achieved, the daily dose can be 
decreased to 15 mg daily followed by careful monitoring of disease and toxicity. Allo-SCT should be con-
sidered, if appropriate. 
 
Toxicity, side-effects and complications  
The toxicity of TKIs has never been the primary endpoint of clinical studies and was not patient-reported. 
Rather, it was evaluated based on the reports of health professionals, using severity scales designed to 
evaluate the acute toxicity of cytotoxic cancer chemotherapy in a clinical setting different from the setting 
of chronic TKI therapy.78 Therefore, it is still difficult to provide a comparative evaluation of the frequency 
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and the severity of toxicities.49 Toxicity has been always reported under the general heading of “adverse 
events”, but two important distinctions should be made. First, hematologic and non-hematologic “ad-
verse events” should be considered separately. Hematologic adverse events (neutropenia, thrombocyto-
penia, anemia) are usually limited to the first treatment period, may require temporary dose adaptation, 
are rarely a cause of treatment changes, and very rarely a cause of complications. There are no data 
showing that the hematologic toxicity of the different TKIs is different, though it may be possible.49 Sec-
ond, non-hematologic “adverse events” should be divided into “side-effects” that affect tolerability and 
life quality and cause a treatment change in as many as 30% of patients, and in “complications” that re-
quire a treatment change in up to 15% of patients, because they may affect significantly patient health 
and life quality, and may sometimes cause death. 
All TKIs have toxicities which may cause clinically relevant complications.49, 79 These must be considered 
when selecting a TKI for a patient with comorbidities80, because some are contraindications for using a 
specific TKI first-line. Previous or concomitant arteriovascular disease represents a strong contraindica-
tion to nilotinib first-line and ponatinib second or third line41, 52, 55, 61, 62, 77, 79, 81, 82, unless there is unique 
need. Respiratory failure and previous or concomitant pleuro-pulmonary disease are strong contraindica-
tions to dasatinib first line. Imatinib should be withheld in patients with significant renal impairment. No 
other strong contraindications to imatinib or to bosutinib have been identified. 
The excess risk of AOE is highest with ponatinib74-77, 82, followed by nilotinib79, and substantially lower 
with other TKIs. For any TKI, QTcF should be measured by electrocardiography prior to commencing and 
subsequently before using any other agent known to increase the QT interval.83, 84  
Pleural effusion is primarily associated with dasatinib, with a 5-year cumulative incidence of 37%. Risk 
factors include older age, twice daily dosing, previous or concomitant cardiac disease or autoimmune 
disorders, hypertension, hypercholesterolemia and advanced phase CML.85 
Diarrhea or constipation may occur with any TKI. Diarrhea is particularly common with bosutinib, though 
this is usually self-limited and may be less problematic with the 400mg dose once daily and with concur-
rent or pre-emptive treatment with loperamide.  
Hepatotoxicity may occur with any TKI, but particularly with bosutinib and nilotinib, although typically this 
consists only of an increase of transaminases rather than more serious evidence of drug-induced liver 
injury. Nilotinib competes for UDP glucuronyl transferase and may result in an unconjugated hyperbiliru-
binemia in patients with Gilbert´s disease without clinical impact. 
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Hyperglycemia occurs mainly with nilotinib. Patients with controlled diabetes mellitus type II or pre-dia-
betes may receive nilotinib if strict glucose monitoring is followed. Nilotinib may also increase serum cho-
lesterol levels associated with AOE. 
Cytopenias often occur during the first weeks of treatment with any TKI reflecting the on-target antileu-
kemic action. If there is slow or poor repopulation by normal hematopoietic cells, cytopenias are likely to 
occur with any TKI and, if severe, may preclude the delivery of an adequate TKI-dose. These patients are 
candidates for supportive care with growth factors and may even require temporary support with blood 
products. If the cytopenias cannot be resolved, the patient should be considered for allo-SCT. Dasatinib, 
a potent SRC-inhibitor, may affect platelet function leading to a bleeding tendency disproportionate to 
the platelet count. 
Elevations of serum lipase, sometimes with clinical manifestations of pancreatitis, have been reported 
after treatment with nilotinib and bosutinib. Therefore, in patients with a history of pancreatitis other 
TKIs are preferred. 
 
Treatment options for resistant BCR-ABL1 mutations 
 
Table 5 
 
Resistance to imatinib occurs in 10%-15%, and to 2GTKI in <10% of patients in first-line treatment. In some 
patients, failure to respond may be related to poor or intermittent compliance with treatment, and these 
patients should be questioned closely about their adherence to the recommended dose and schedule of 
medication. Resistance may be caused by a BCR-ABL1 kinase domain (KD)-mutation coding for a BCR-ABL1 
protein that is poorly inhibited by TKIs. Mutations account for resistance in about one third of resistant 
CP patients, and in about two thirds of resistant AP and BP patients. Alternative mechanisms of resistance 
include clonal evolution (additional chromosomal aberrations, ACA) and the activation of BCR-ABL1 inde-
pendent pathways. Not all ACA indicate progression equally. A cytogenetic risk classification has therefore 
been proposed to allow risk-based treatment adaptation.17, 86 
BCR-ABL1 mutations can be detected with sensitivities of about 20% by Sanger sequencing and of about 
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3% by NGS. The greater sensitivity of NGS enables the detection of clinically relevant BCR-ABL1 resistance 
mutations.87, 88 NGS is the recommended technology to detect BCR-ABL1 resistance mutations in patients 
not responding adequately to TKI.  
In about two-thirds of resistant CP patients and in about one third of resistant AP and BP patients, a mu-
tation is neither detected, nor is it the only cause of resistance, after compliance has been verified. In the 
future, analysing the genome and expression profiles of resistant CML cells may lead to identifying so-
matic mutations89-91 as early signs of progression and to a genomically based risk classification with the 
potential for non-BCR-ABL1 targeted therapy for resistant patients.  
The phenomenon of the so-called clinical cure, namely the persistence of detectable leukemic cells while 
either on treatment or off-treatment in DMR, differs from resistance. This is likely governed by different 
factors, such as the immune control of minimal residual disease and the type of BCR-ABL1 transcript, 
because e13a2 (b2a2) cells are more persistent than e14a2 (b3a2) transcripts.92  
 
Treatment of advanced-phase CML 
Progression of CML to end-phase has fortunately become a rare event. End-phase CML comprises early 
progression with emerging high-risk ACA and late progression with failing hematopoiesis and blast cell 
proliferation. BP is a late feature of progression.93 Currently, diagnosis rests on the percentage of blasts 
(20% or 30%) in blood or marrow.6, 94 Not all patients dying of CML reach the BP-defining blast levels.95  
Once BP has occurred, survival is generally less than one year with death due to infection or bleeding. 
Early indicators of progression are the appearance of ACA16-18, somatic mutations90, 91 and occasionally 
clinical deterioration without obvious explanation. Flow cytometry distinguishes between lymphoid and 
myeloid BP allowing appropriate selection of treatment. Lymphoid BP has more treatment options and a 
better outcome than myeloid BP.  
After KD-mutation analysis, treatment consists of intensive combination chemotherapy with or without a 
TKI in preparation for a prompt allo-SCT if possible (Table 6). In patients with resistance to a 2GTKI without 
specific mutations ponatinib is preferred over change of 2GTKI, unless cardiovascular risk factors are pre-
sent.77 In patients who cannot tolerate intensive chemotherapy regimens, a more palliative approach with 
less intensive therapy according to immunophenotype should be considered. 
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Table 6 
 
Allogeneic stem cell transplantation (allo-SCT) 
In first CP (CP1) allo-SCT still has a place in managing the small number of patients with disease resistant 
or intolerant to multiple TKIs, and for the very rare patient with inadequate recovery of normal hemato-
poiesis. In resource-poor countries, allo-SCT may have priority over TKI-treatment as the one-time ex-
penses of transplantation are more economical than life-long drug costs. 
For a patient who is resistant to the initial 2GTKI given either as first or second-line therapy, the chance 
of achieving a durable response to an alternative 2GTKI is low, and ponatinib or an experimental agent 
should be considered (Table 6). At this juncture the patient should also be assessed for allo-SCT and a 
donor search initiated. Failure to respond to ponatinib after 3 months´ treatment indicates a patient at 
high risk of progression, and an early transplant is indicated. The patient should be assessed for allo-SCT 
and a donor search initiated. 
A patient presenting in AP should be treated as a high-risk patient, becoming eligible for allo-SCT if the 
response is not optimal. A patient progressing to AP during treatment should immediately be considered 
for allo-SCT. 
For patients presenting in, or progressing to BP, the long-term outcome with any of the currently available 
TKI is poor96; every effort should be made to offer allo-SCT after initial control of their disease. Patients 
returning to a second CP (CP2) before allo-SCT have improved transplantation outcomes.97, 98 The addition 
of a TKI to chemotherapy-based AML99, 100 or ALL regimens101 improves the chance of achieving CP2.  The 
choice of TKI should be based on prior therapies and BCR-ABL1 KD-mutational status. If CP2 is achieved, 
patients should proceed to allo-SCT without delay, as PFS in BP is low and time to allo-SCT plays a crucial 
role.102 Transplantation in frank BP is not recommended.  
 
Quality of life 
TKIs have improved patient outcomes to near-normal, and thereby survival, so that quality of life during 
treatment is clearly important. There are few quantitative studies, and many focus on comparisons of 
tolerability of different TKIs which is only one aspect of life-quality.103-109 Since all patients receive TKIs for 
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many years, and the majority currently remain on treatment indefinitely, we encourage additional re-
search in this area and the use of patient-reported outcome (PRO) questionnaires which may provide 
guidance about quantifying and addressing chronic issues faced by CML patients12. 
 
Treatment-free remission 
A significant proportion of patients will achieve a DMR defined as BCR-ABL1 levels of MR4 and MR4.5 on 
the IS with the familiar TKIs. Table 7 lists benchmarks of DMR that can be expected by 5 and 10 years.36, 
37, 40, 41, 52 Five-year follow-up of first-line bosutinib is not yet available. An attempt at treatment discon-
tinuation can be considered, if sustained DMR of sufficiently long duration has been achieved.  
 
Table 7 
 
The first prospective proof of concept for stopping TKI treatment was the Stop Imatinib 1 (STIM1) trial 
which showed that 38 % of the patients maintained a molecular remission after a median follow-up of 77 
months.110 The eligibility criteria for stopping treatment was around MR4.5 sustained for the two years 
before stopping. 
Since then, multiple trials have been conducted or are still ongoing, each of which used slightly different 
entry criteria and different triggers for restarting the TKI. A meta-analysis of 15 cohort studies including 
more than 500 patients after imatinib cessation demonstrated a mean molecular recurrence rate after 
imatinib cessation of 51% illustrating the high reproducibility of the results.111 More recently, the large 
EURO-SKI study evaluated 755 patients with similar overall results.112  A consistent inclusion criterion in 
most studies was a minimum duration of TKI therapy of 3 years and a sustained DMR of at least one year. 
Recent data suggest that the TFR success rate for patients with stable MMR, but not achieving DMR is 
significantly lower than for stable DMR113; this observation requires confirmation. 
Of importance, more than 80% of recurrences occur within the first 6-8 months after stopping emphasiz-
ing the need for frequent monitoring and structured follow-up during this early period.  Stopping treat-
ment is a safe procedure at centers with access to high quality molecular monitoring and with careful 
patient selection. Some patients otherwise eligible for TFR prefer to remain on therapy, and it is important 
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that clinicians discuss the available data with patients before a TFR attempt is begun. Loss of MMR has 
been the trigger for restarting therapy in most studies.114 Confirmation of loss of MMR on a second occa-
sion is not considered necessary and could delay restarting therapy.  It should be emphasized that some 
patients have fluctuating values between MMR and MR4 values which sometimes improve over time with-
out restarting TKI; such patients require careful serial monitoring.  About 90-95% of patients who experi-
ence molecular recurrence regain their initial molecular level after restarting TKI therapy.  Usually, the 
same TKI is restarted, unless prior side effects indicate a change.  So far, very few of >3000 patients who 
have been followed in TFR trials have had unfavorable outcomes: one patient had loss of MMR due to 
mutation, one had loss of cytogenetic remission, and one had progression to BP, but it is likely that num-
bers increase with more patients observed over longer times. 
Loss of MMR is uncommon after one year in TFR although continued long-term monitoring is recom-
mended because the follow-up of all these studies is less than ten years and it is unknown whether or 
how often late relapses might occur. The mechanism(s) which prevent recurrence are not understood and 
are under investigation focussing on possible immune-mediated control of residual disease.    
After stopping nilotinib or dasatinib as either first or second-line therapy, the probability of maintaining 
TFR has been ~ 50%115-117, similar to the results after stopping imatinib. 
Different prognostic factors for TFR success have been reported. Longer durations of TKI therapy and DMR 
and prior treatment with IFN were identified as important indicators for maintaining MMR at 6 months 
in EURO-SKI, the largest TFR trial so far; of these, duration of DMR seemed to be the most important 
factor.91  
A characteristic polymyalgia-like syndrome of musculoskeletal and/or joint pain beginning the first weeks 
or months after TKI discontinuation has been reported in about 20-30% of patients.118 This phenomenon 
is likely due to undefined off-target effect(s) of the TKI. In most patients the symptoms are mild and self-
limited, but some patients may require temporary treatment with acetaminophen, nonsteroidal anti-in-
flammatory drugs or in some instances a short course of oral corticosteroids. 
The ELN panel recommendations for TKI discontinuation are summarized in Table 8.119, 120  
 
Table 8 
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The panel agrees that TFR is a new significant goal of CML management. It recommends consideration of 
TFR in appropriate patients after careful discussion employing the concept of shared decision making.121 
Treatment may be changed to 2GTKI to improve the depth of response in selected patients in whom DMR 
has not been reached. In special situations such as the motivated patient with a high priority for TFR, 
younger patients with low or intermediate risk disease or women who wish to become pregnant, a change 
to 2GTKI is recommended for consideration.  
 
Pregnancy and parenting 
Many patients of child-bearing potential seek advice regarding the effects of CML and TKI regarding fer-
tility, pregnancy and effects on offspring. Sensitive, informed communication is mandatory, as is good 
collaboration with obstetric colleagues. 
For men taking imatinib, bosutinib, dasatinib, or nilotinib, there is no increased risk of congenital abnor-
malities in their offspring.122-127 Data are sparse/absent for ponatinib and asciminib respectively. Changes 
in sperm quality and morphology can be present at diagnosis and are unchanged after imatinib.128 There-
fore, men planning fatherhood do not need to discontinue treatment with imatinib or 2GTKI. 
For women, management of CML occurring during pregnancy must be individualized. In general, TKIs are 
not recommended, but with close monitoring, a normal baby is not impossible. Preferably, TKI treatment 
should be discontinued in the first trimester, as soon as pregnancy is confirmed. Fetal ultrasonography 
should be performed immediately. Options of continuing or discontinuing treatment and continuation of 
pregnancy or not should be exhaustively discussed.  
The teratogenicity of TKI is likely due to PDGFR inhibition during organogenesis. The occurrence of hy-
drops fetalis when dasatinib was commenced in the second trimester123 suggest all TKIs are contraindi-
cated throughout pregnancy. Although imatinib has been used safely in the second and third trimesters, 
insufficient experience with it does not allow its routine use.126, 129  
While termination of the pregnancy in chronic phase is not mandatory, it is a consideration in more ad-
vanced disease. If the white blood cell count is low, CML treatment may not be required before delivery. 
Aspirin and/or low molecular weight heparin are indicated for thrombocytosis. Leucapheresis and/or IFN 
are safe throughout gestation.122, 130 Close collaboration with obstetricians and regular fetal ultrasound 
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examinations are recommended. Low-level secretion of TKI in breast milk contraindicates their use during 
breast-feeding.131 
Women eligible for a trial of TFR can also safely discontinue their TKI in order to conceive. Management 
thereafter depends on maintenance or loss of MMR. Women who lose MMR and are pregnant are likely 
to reach term without a clinical need for restarting treatment. Women who lose MMR and are not yet 
pregnant should restart treatment, perhaps with a more potent TKI, and could try to discontinue again 
when deep molecular response has been re-established and maintained for the appropriate time. More 
challenging is the woman desiring pregnancy without a sustained DMR (often associated with older age 
and/or societal pressures). Possible solutions include substitution of TKI with IFN or referral for alterna-
tive methods for conception. 
 
Discussion 
New developments and findings prompted this fourth version of the ELN management recommendations. 
All randomized studies comparing imatinib 400 mg once daily with 2GTKIs, imatinib 400mg with dose 
increase, or imatinib combined with IFN or low-dose cytarabine have failed to improve OS. Although 
deeper molecular responses occurred more rapidly with 2GTKIs, it did not translate into better OS than 
with imatinib at a standard dose of 400mg daily. These studies, however, provided greater insights in the 
safety and efficacy of the drugs, as well as benchmarks for molecular response as a basis for individualized 
treatment and eventually treatment discontinuation. The studies showed that survival has moved close 
to that of the general population. Now more patients die of CML-unrelated causes than from CML. Alt-
hough no new serious late side-effects of imatinib have surfaced over 20 years, chronic low-grade fatigue 
and muscle cramps remain issues for many patients remaining on treatment.  
Another very important development has been the recognition that treatment can be successfully 
stopped in some patients if the duration of both treatment and DMR are sufficient to make TFR feasible 
for potential cure. The panel agreed that TFR is an important new goal of CML management which should 
be discussed with appropriate patients.121  
There was considerable discussion, but with no final consensus, regarding the advisability of changing 
therapy (usually from imatinib to a 2GTKI) in a patient with stable CCyR or MMR, but in whom the level 
of DMR (<MR4) was insufficient to warrant consideration of discontinuation. A change from 2GTKI to 
imatinib can be considered when no DMR is achieved within 5 years to avoid the risk of serious cumulative 
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toxicity of 2GTKI. There is no information about the rate of successful TFR from large randomized trials 
with different initial treatment regimens addressing this specific issue. 
The ENESTcmr trial132, 133 provides some relevant information, however. In what was termed “persistent 
molecular disease”, those patients who had achieved CCyR were randomized to continuing imatinib or 
switching to nilotinib 400 mg twice daily.  The rate of achieving MR4.5 was higher in the nilotinib recipients 
(54% vs 45% [32% in imatinib patients who did not cross over to nilotinib]).  But, only 57% of patients 
completed 48 months of nilotinib therapy and 13% of patients randomized to nilotinib experienced sig-
nificant cardiovascular events. There was no information whether patients who reached the MR4.5 end-
point successfully achieved TFR subsequently. An ongoing randomized study, SUSTRENIM 
(NCT02602314), will provide information on TFR rates after patients treated for 4 years with either ni-
lotinib or imatinib (with change to nilotinib if treatment milestones are not reached). Treatment cessation 
will be offered after at least 1 year in MR4. 
Advocates for a change of therapy argued that this approach could increase the number of patients in 
whom treatment can be stopped successfully.  Arguments against pointed to the potentially more serious 
side effects of 2GTKI, their increased costs and absent information about the number of patients who 
might actually benefit. Many more patients would be exposed to these side effects compared to those 
expected to benefit and successfully reach TFR. In view of the limited data and the investigational require-
ments to answer these questions, the panel does not recommend a first-line 2GTKI, or a change to a 
2GTKI, for faster DMR, but agrees that a change may be considered in selected patients.  These might 
include:  younger patients with low- or intermediate-risk disease, patients for whom TFR is a high priority, 
and women who wish to become pregnant. Other important points: 
• The new ELTS risk score has been helpful in predicting the rate of death from CML in TKI treated 
patients. The panel recommends using this score instead of the older ones. It is noteworthy that 
the ELTS score uses the same variables as the Sokal score, but with different weights. 
• Good quality molecular testing is now available worldwide replacing cytogenetic monitoring in 
most situations and obviating the need for bone marrow aspirations. If a change in therapy is un-
der consideration because of inadequate response or disease progression (drug resistance), a mar-
row aspiration is recommended to assesss for cytogenetic clonal evolution. BCR-ABL1 KD-muta-
tion analysis should also be done in such circumstances.  
• New developments have also occurred in first-line therapy. Generic imatinib is now available 
worldwide at low cost. Dasatinib will soon become generic. Bosutinib is available first-line with a 
safety profile different from other 2GTKIs, and radotinib is approved first-line in Korea.   Ponatinib 
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remains the only TKI with activity against the T315I mutation, though it should not be used first-
line. Trials are underway to assess whether the high level of response can be maintained with 
decreased cardiovascular risk using lower doses of the drug. Asciminib appears to be a drug of 
promise but more information is required.134 
Assuming continued compliance with medication, sustained CCyR (equivalent to <1% on the IS), MMR and 
DMR predict excellent long-term outcome. Progression to advanced phase is rare (less than 2 per thou-
sand patient-years with MMR). Continued molecular monitoring is nevertheless recommended indefi-
nitely.  
• Allo-SCT remains an important option for patients resistant or intolerant to 2 or more TKIs and for 
the approximately 6% of patients who still progress to BP. 
• All TKI are teratogenic and are preferentially contraindicated during pregnancy. 
• PEG-IFN in combination with a TKI may also accelerate or deepen a molecular response, but 
currently remains investigational. Randomized comparisons of nilotinib with and without PEG-
IFN are underway. 
The vision for the next 5 years is that more CML patients will successfully achieve TFR and that it will be 
possible to talk more confidently about the curability of CML. 
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Tables 
 
Table 1. Diagnostic work-up, baseline 
 
- Physical examination with particular reference to spleen and liver size 
- Complete blood cell count with microscopic differential 
- Bone marrow aspirate for cytologic examination and cytogenetics; core biopsy if dry tap 
- Chromosome banding analysis (CBA)  
- Fluorescence in-situ hybridization (FISH) only in case of Ph-negativity 
- Qualitative reverse transcriptase polymerase chain reaction (PCR) for the detection of BCR-ABL1 
transcripts and identification of the transcript type 
- Electrocardiogram 
- Standard biochemical profile with hepatitis B-serology 
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Table 2. Prognostic scores at baseline and comparison of Sokal21 and ELTS24 scores 
 
A) Score calculation 
 
 Score Calculation Definition of risk groups 
 Sokal   Exp 0.0116 ×  (age - 43.4)  
+ 0.0345      ×  (spleen - 7.51)  
+ 0.188        ×  [(platelet count/700)2 - 0.563]  
+ 0.0887      ×  (blood blasts - 2.10) 
Low-risk: < 0.8 
Intermediate-risk: 0.8 - 1.2 
High-risk: > 1.2 
  
 ELTS   0.0025        ×  (age/10)3  
+ 0.0615      ×  spleen size  
+ 0.1052      ×  peripheral blood blasts  
+ 0.4104      ×  (platelet count/1000)–0.5 
Low-risk: < 1.5680 
Intermediate-risk:1.5680- 2.2185 
High-risk: > 2.2185 
 
B) Risk strata proportions and outcome 
 
 Low risk Intermediate risk High risk 
n = 5154 Sokal ELTS Sokal ELTS Sokal ELTS 
% 38 55 38 28 23 13 
10 year OS 89% 88% 81%  79% 75% 68% 
6 year LRD 3% 2% 4% 5% 8%  12% 
 
ELTS: EUTOS score for long-term survival considering leukemia-related death (LRD); OS: overall survival; 
age given in years; spleen size in cm below costal margin measured by palpation (maximum distance); 
blasts in percent of peripheral blood differential; platelet count, 109/L. All values are pre-treatment. To 
calculate Sokal and ELTS scores, go to  
http://www.leukemia-net.org/content/leukemias/cml/elts_score/index_eng.html.  
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Table 3. Reference gene numbers required for scoring molecular response29, 31 
 
 MMR MR4 MR4.5 MR5 
Minimum sum of  
reference gene transcripts 
10,000 ABL1* 
24,000 GUSB* 
10,000 ABL1 
24,000 GUSB 
32,000 ABL1 
77,000 GUSB 
100,000 ABL1 
240,000 GUSB 
BCR-ABL1 transcript level  
on the IS**  
≤0.1% ≤0.01% ≤0.0032% ≤0.001% 
 
* Minimal sensitivity for accurate quantification 
**International Scale, IS 
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Table 4: Milestones for treating CML expressed as BCR-ABL1 on the International Scale (IS) 
 
 Optimal Warning Failure 
Baseline      NA High-risk ACA, high-risk ELTS 
score 
NA 
3 months      ≤ 10%  >10%  >10% if confirmed within 
1-3 months 
6 months  ≤ 1%  >1%-10% >10% 
12 months  ≤ 0.1%  >0.1%-1% >1% 
 Any time  ≤ 0.1%  >0.1%, 
 loss of ≤ 0.1% (MMR)*  
>1%, resistance muta-
tions, high-risk ACA 
 
*Loss of MMR (BCR-ABL1 >0.1%) indicates failure after TFR.  
For patients aiming at TFR, the optimal response (at any time) is BCR-ABL1 <0.01% (MR4).  
A change of treatment may be considered if MMR is not reached by 36-48 months.  
NA, not applicable; ELTS, EUTOS long term survival score. 
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Table 5: Recommended tyrosine kinase inhibitors in case of BCR-ABL1 resistance mutations 
 
T315I Ponatinib 
F317L/V/I/C, T315A Nilotinib, bosutinib* or ponatinib  
V299L Nilotinib or ponatinib 
Y253H, E255V/K, F359V/I/C Dasatinib, bosutinib* or ponatinib  
 
*There are limited data available regarding mutations associated with clinical resistance to bosutinib in 
vivo. Some in vitro data suggests that the E255K and, to a lesser extent, the E255V mutation, might be 
poorly sensitive to bosutinib.  
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Table 6: Management strategy recommendations for end-phase CML 
 
Prevention by elimination of BCR-ABL1 Assurance of effective TKI treatment 
Early: emergence of high-risk ACA Observe closely, consider intensification of treat-
ment (ponatinib, early allo-SCT) 
Primary blast phase Start with imatinib, change to a 2GTKI according 
to KD-mutation profile. 
Resistance to 2GTKI (first or second line) Ponatinib or experimental agent. 
Assessment for allo-SCT, donor search. 
Failure to ponatinib High-risk of progression, early allo-SCT recom-
mended 
Accelerated phase To be treated as high-risk patients; proceed to 
allo-SCT if response not optimal.  
Progress to blast phase Attempt at return to CP2. 
Outcome with currently available TKI poor. 
Addition of chemotherapy based on AML regi-
mens for myeloid BP (such as dasatinib or 
ponatinib + FLAG-IDA) or acute lymphoblastic leu-
kemia regimens for lymphoid BP (such as imatinib 
or dasatinib + hyperfractionated CVAD) recom-
mended.  
Choice of TKI should be based on prior therapy 
and BCR-ABL1 KD-mutational status. 
After CP2 is achieved proceed to allo-SCT without 
delay.  
 
ACA, additional chromosomal aberrations; allo-SCT, allogeneic stem cell transplantation;  
2GTKI, second generation tyrosine kinase inhibitor; CP1, first chronic phase; CP2, second chronic phase; 
BP, blast phase. 
  32 
Table 7: Cumulative Incidence of deep molecular response (MR4 and MR4.5) with imatinib, nilotinib, and 
dasatinib by 5 and 10 years 
 
Study 
 
5 years (%) 10 years (%) 
CML-Study IV*36, 37 Imatinib MR4  68 81 
Imatinib MR4.5  53 72 
ENESTnd **41, 52      Nilotinib MR4  66 73 
Nilotinib MR4.5  54 64 
Imatinib MR4 42 56 
Imatinib MR4.5 35   45 
Dasision ***40  Dasatinib MR4.5  42 NA 
Imatinib MR4.5  33 NA 
 
*imatinib (n=1442), **nilotinib 300 mg twice daily (n=282), imatinib 400mg daily (n=283), ***dasatinib 
100mg once daily (n=259), imatinib 400 mg daily (n=260) 
DMR rates of these trials cannot be directly compared owing to different methods of trial evaluation. 
NA = not available 
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Table 8: Requirements for tyrosine kinase inhibitor discontinuation 
Mandatory: 
• CML in first CP only (data are lacking outside this setting) 
• Motivated patient with structured communication 
• Access to high quality quantitative PCR using the International Scale (IS) with rapid turn-around 
of PCR test results 
• Patient's agreement to more frequent monitoring after stopping treatment. This mean monthly 
for the first 6 months, every 2 months for months 6-12, and every 3 months thereafter. 
Minimal (stop allowed):  
• First-line therapy or second-line if intolerance was the only reason for changing TKI 
• Typical e13a2 or e14a2 BCR–ABL1 transcripts 
• Duration of TKI therapy >5 years (>4 years for 2GTKI) 
• Duration of DMR (MR4 or better) >2 years 
• No prior treatment failure 
Optimal (stop recommended for consideration): 
• Duration of TKI therapy >5 years 
• Duration of DMR >3 years if MR4 
• Duration of DMR >2 years if MR4.5 
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